Nanobiotix S.A. (NBTX) — AI-Aktienanalyse

Nanobiotix S.A. is a clinical-stage biotechnology company specializing in nanoparticle-based cancer therapies. Their lead product, NBTXR3, enhances the effectiveness of radiation therapy across multiple cancer types.

Unternehmensueberblick

Kurzfassung:

Nanobiotix S.A. is a clinical-stage biotechnology firm focused on revolutionizing cancer treatment through nanoparticle technology, specifically NBTXR3, which enhances radiation therapy's efficacy. With a partnership with LianBio for expansion in Asia, Nanobiotix is positioned to address significant unmet needs in oncology, though profitability remains a challenge.

Ueber NBTX

Nanobiotix S.A., founded in 2003 and headquartered in Paris, France, is a clinical-stage biotechnology company dedicated to transforming cancer treatment. The company's core technology revolves around nanoparticle-based solutions designed to enhance the efficacy of radiation therapy. Their lead product candidate, NBTXR3, is a sterile aqueous suspension of crystalline hafnium oxide nanoparticles. This innovative product is being developed for a wide range of cancer indications, including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. NBTXR3 is designed to be injected directly into the tumor prior to radiation therapy. The nanoparticles amplify the effects of radiation within the tumor, leading to increased tumor cell destruction without increasing the radiation dose to surrounding healthy tissues. This targeted approach has the potential to improve treatment outcomes and reduce side effects for cancer patients. Nanobiotix has strategically partnered with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. This partnership provides Nanobiotix with access to key Asian markets and leverages LianBio's expertise in clinical development and commercialization in the region. The company operates with a team of 108 employees, focusing on research, development, and strategic partnerships to advance its pipeline of cancer therapies.

Investmentthese

Nanobiotix presents a notable market position in the oncology space, driven by its innovative NBTXR3 nanoparticle technology. The company's lead product has shown promise in enhancing radiation therapy across various cancer types, potentially improving treatment outcomes and reducing side effects. The partnership with LianBio provides access to high-growth Asian markets, offering significant revenue potential. However, the company's negative profit margin of -899.7% and reliance on clinical trial success pose substantial risks. The current market capitalization of $1.60 billion reflects investor optimism, but future success hinges on positive clinical data and regulatory approvals. Upcoming trial results will be critical for validating the technology and driving shareholder value.

Branchenkontext

Nanobiotix operates within the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The oncology market is a significant segment within the biotechnology industry, driven by the increasing prevalence of cancer and the demand for more effective and less toxic treatments. Nanobiotix's nanoparticle technology offers a unique approach to enhancing radiation therapy, potentially differentiating it from traditional cancer treatments and competitive approaches from companies like ABUS and KURA. The industry is also seeing trends toward personalized medicine and targeted therapies, aligning with Nanobiotix's focus on localized tumor treatment.

Biotechnology

Healthcare

Wachstumschancen

Growth opportunity 1: Expansion into new cancer indications represents a significant growth opportunity for Nanobiotix. NBTXR3 is currently being evaluated in clinical trials for various cancer types, including head and neck cancers, liver cancers, and prostate cancer. Positive clinical data and regulatory approvals in these new indications could significantly expand the addressable market for NBTXR3, potentially reaching billions of dollars. The timeline for this expansion depends on the successful completion of ongoing clinical trials and subsequent regulatory submissions.
Growth opportunity 2: Commercialization in Asian markets through the partnership with LianBio offers substantial growth potential. The prevalence of cancer is increasing in Asia, and there is a growing demand for innovative cancer treatments. LianBio's expertise in clinical development and commercialization in the region positions Nanobiotix to effectively penetrate these markets. The timeline for commercialization depends on regulatory approvals in each country, but the potential revenue from these markets is significant.
Growth opportunity 3: Development of next-generation nanoparticle technologies could further enhance Nanobiotix's competitive advantage. The company is actively engaged in research and development to improve the efficacy and safety of its nanoparticle platform. These advancements could lead to the development of new products and applications, expanding the company's pipeline and market opportunities. The timeline for these developments is uncertain, but the potential long-term impact is substantial.
Growth opportunity 4: Strategic partnerships with other pharmaceutical companies could accelerate the development and commercialization of NBTXR3. Collaborations with companies that have complementary expertise in drug development, manufacturing, or marketing could provide Nanobiotix with access to additional resources and capabilities. These partnerships could also help to reduce the financial risk associated with clinical development and commercialization. The timing and nature of these partnerships are uncertain, but they could significantly enhance the company's growth prospects.
Growth opportunity 5: Potential for NBTXR3 to become a standard of care in combination with radiation therapy across multiple cancer types. As clinical data continues to demonstrate the efficacy and safety of NBTXR3, it could become a preferred treatment option for oncologists. This would lead to increased adoption of NBTXR3 and significant revenue growth for Nanobiotix. Achieving this status depends on continued positive clinical trial results and successful commercialization efforts.

Market capitalization of $1.60 billion reflects investor confidence in Nanobiotix's technology and pipeline.
Gross margin of 100.0% indicates strong potential profitability upon commercialization, although current operating expenses result in a negative profit margin.
Partnership with LianBio provides access to the Greater China, South Korea, Singapore, and Thailand markets, representing a significant growth opportunity.
Beta of 0.57 suggests lower volatility compared to the overall market, potentially making it a more stable investment in the biotechnology sector.
Lead product candidate NBTXR3 targets a wide range of cancer indications, including soft tissue sarcoma, head and neck cancers, and liver cancers, diversifying its potential market.

Was das Unternehmen tut

Develop nanoparticle-based cancer therapies.
Enhance the efficacy of radiation therapy with NBTXR3.
Target a wide range of cancer indications, including soft tissue sarcoma and head and neck cancers.
Partner with LianBio to commercialize NBTXR3 in Asian markets.
Conduct clinical trials to evaluate the safety and efficacy of NBTXR3.
Focus on localized tumor treatment to minimize side effects.

Geschaeftsmodell

Develop and commercialize nanoparticle-based cancer therapies.
Generate revenue through product sales and licensing agreements.
Partner with other companies to expand market reach and share development costs.

Hospitals and cancer treatment centers.
Oncologists and radiation oncologists.
Patients with cancer.

Proprietary nanoparticle technology with patent protection.
Clinical data demonstrating the efficacy and safety of NBTXR3.
Partnership with LianBio providing access to key Asian markets.
First-mover advantage in the development of nanoparticle-based radiation enhancers.

Katalysatoren

Upcoming: Publication of clinical trial results for NBTXR3 in head and neck cancers (Q2 2026).
Ongoing: Enrollment and progress in ongoing clinical trials for NBTXR3 in liver cancers and prostate cancer.
Upcoming: Potential regulatory approvals for NBTXR3 in Asian markets through the LianBio partnership (H2 2026).
Ongoing: Expansion of strategic partnerships with other pharmaceutical companies.
Ongoing: Development of next-generation nanoparticle technologies.

Risiken

Potential: Unfavorable clinical trial results for NBTXR3.
Potential: Regulatory hurdles and delays in key markets.
Ongoing: Competition from other cancer treatment companies.
Ongoing: High research and development costs.
Potential: Product liability risks.

Staerken

Innovative nanoparticle technology with potential to enhance radiation therapy.
Clinical data demonstrating efficacy and safety of NBTXR3.
Partnership with LianBio providing access to key Asian markets.
Strong intellectual property portfolio protecting its technology.

Schwaechen

Clinical-stage company with no currently approved products.
High research and development costs.
Negative profit margin.
Reliance on clinical trial success and regulatory approvals.

Chancen

Expansion into new cancer indications.
Commercialization in Asian markets through the LianBio partnership.
Development of next-generation nanoparticle technologies.
Strategic partnerships with other pharmaceutical companies.

Risiken

Competition from other cancer treatment companies.
Regulatory hurdles and delays.
Unfavorable clinical trial results.
Product liability risks.

Wettbewerber & Vergleichsunternehmen

Arbutus Biopharma Corporation — Focuses on developing novel hepatitis B virus (HBV) therapeutics. — (ABUS)
EyePoint Pharmaceuticals, Inc. — Specializes in sustained-release therapeutics for eye diseases. — (EYPT)
Guardforce AI Co., Limited — Provides security solutions and services, unrelated to Nanobiotix's oncology focus. — (GHRS)
Kura Oncology, Inc. — Develops precision medicines for genetically defined cancers. — (KURA)
Lenz Therapeutics, Inc. — Focuses on developing pharmaceutical products for the treatment of presbyopia. — (LENZ)

Key Metrics

Price: $29.55 (-2.84%)
Market Cap: $2
P/E Ratio: 110.47
Volume: NaN
MoonshotScore: 51/100

Analyst Price Target

Analyst Consensus Target: $27.26
Current Price: $29.55
Implied Upside: -7.7%

Company Profile

CEO: Laurent Levy
Headquarters: Paris, FR
Employees: 108
Founded: 2020

AI Insight

Nanobiotix S.A. is a clinical-stage biotechnology company focused on developing cancer treatments. Their lead product candidate is NBTXR3, a nanoparticle suspension used in radiation therapy. They have a partnership with LianBio to develop and commercialize NBTXR3 in specific Asian markets.

ADR Level: 2
ADR Ratio: 1:1

Fragen & Antworten

What does Nanobiotix S.A. do?

Nanobiotix S.A. is a clinical-stage biotechnology company focused on developing innovative cancer treatments using nanoparticle technology. Their lead product candidate, NBTXR3, is designed to enhance the efficacy of radiation therapy by amplifying the radiation dose within the tumor while minimizing damage to surrounding healthy tissues. The company is currently conducting clinical trials to evaluate NBTXR3 in various cancer types and has partnered with LianBio to commercialize NBTXR3 in key Asian markets. Nanobiotix aims to improve cancer treatment outcomes and reduce side effects for patients.

What do analysts say about NBTX stock?

Analyst coverage of Nanobiotix (NBTX) is focused on the potential of its NBTXR3 product and its impact on cancer treatment. Key valuation metrics include the company's market capitalization and its potential revenue from future product sales. Growth considerations center on the successful completion of clinical trials, regulatory approvals, and commercialization efforts, particularly in Asian markets through the LianBio partnership. Analyst consensus is cautiously optimistic, recognizing the potential of Nanobiotix's technology but also acknowledging the risks associated with clinical-stage biotechnology companies. No buy/sell recommendations are made.

What are the main risks for NBTX?

Nanobiotix faces several risks inherent to the biotechnology industry. These include the potential for unfavorable clinical trial results, which could delay or halt the development of NBTXR3. Regulatory hurdles and delays in key markets could also impact the company's ability to commercialize its products. Competition from other cancer treatment companies poses a threat to Nanobiotix's market share. Additionally, the company faces financial risks associated with high research and development costs and the need to secure additional funding. Product liability risks are also a concern, given the nature of cancer treatments.

Is NBTX a good investment right now?

Use the AI score and analyst targets on this page to evaluate Nanobiotix S.A. (NBTX). Our analysis considers fundamentals, technicals, and market sentiment to help you decide.

What is the MoonshotScore for NBTX?

The MoonshotScore is a proprietary 0-100 AI rating that evaluates Nanobiotix S.A. across multiple dimensions including financial health, growth trajectory, and risk factors.

Where can I find NBTX financial statements?

Nanobiotix S.A. financial data including revenue, earnings, and balance sheet metrics are available in the Financials tab on this page, sourced from institutional-grade data providers.

What do analysts say about NBTX?

Analyst consensus targets and ratings for Nanobiotix S.A. are shown in the analysis section. These are aggregated from major Wall Street firms and updated regularly.

How volatile is NBTX stock?

Check the beta and historical price range on this page to assess Nanobiotix S.A.'s volatility relative to the broader market.